Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification

Broad spectrum antiviral drugs targeting host processes could potentially treat a wide range of viruses while reducing the likelihood of emergent resistance. Despite great promise as therapeutics, such drugs remain largely elusive. Here we use parallel genome-wide high-coverage shRNA and CRISPR-Cas9 screens to identify the cellular target and mechanism of action of GSK983, a potent broad spectrum antiviral with unexplained cytotoxicity1–3. We show that GSK983 blocks cell proliferation and dengue virus replication by inhibiting the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH). Guided by mechanistic insights from both genomic screens, we found that exogenous deoxycytidine markedly reduces GSK983 cytotoxicity but not antiviral activity, providing an attractive novel approach to improve the therapeutic window of DHODH inhibitors against RNA viruses. Together, our results highlight the distinct advantages and limitations of each screening method for identifying drug targets and demonstrate the utility of parallel knockdown and knockout screens for comprehensively probing drug activity.

[1]  Pamela L. Golden,et al.  Tetrahydrocarbazole amides with potent activity against human papillomaviruses. , 2009, Bioorganic & medicinal chemistry letters.

[2]  D. E. Patterson,et al.  Efficient Asymmetric Synthesis of N-[(1R)-6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]-2-pyridinecarboxamide for Treatment of Human Papillomavirus Infections , 2007 .

[3]  P. Clemons,et al.  Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.

[4]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[5]  Avi Ma'ayan,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[6]  P. Shi,et al.  Characterization of Dengue Virus Resistance to Brequinar in Cell Culture , 2010, Antimicrobial Agents and Chemotherapy.

[7]  J. Roehrig,et al.  Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. , 1997, Virology.

[8]  Wei Zhang,et al.  Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System , 2014, Cell.

[9]  L. Kramer,et al.  Inhibition of Dengue Virus through Suppression of Host Pyrimidine Biosynthesis , 2011, Journal of Virology.

[10]  S. Bavari,et al.  Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. , 2012, Antiviral research.

[11]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[12]  J. Neyts,et al.  Intervention strategies for emerging viruses: use of antivirals , 2013, Current Opinion in Virology.

[13]  Michael T. McManus,et al.  Rapid Creation and Quantitative Monitoring of High Coverage shRNA Libraries , 2009, Nature Methods.

[14]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[15]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[16]  Michael I. Jordan,et al.  Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Sabatini,et al.  Regulation of mTORC1 by amino acids. , 2014, Trends in cell biology.

[18]  M. Kinch,et al.  Development of a broad-spectrum antiviral with activity against Ebola virus. , 2009, Antiviral research.

[19]  A. Gamarnik,et al.  Dengue Virus Capsid Protein Usurps Lipid Droplets for Viral Particle Formation , 2009, PLoS pathogens.

[20]  Max A. Horlbeck,et al.  Next-generation libraries for robust RNA interference-based genome-wide screens , 2015, Proceedings of the National Academy of Sciences.

[21]  John A. Tallarico,et al.  Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV) , 2011, Proceedings of the National Academy of Sciences.

[22]  N. Krogan,et al.  Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response , 2015, eLife.

[23]  John S. Brownstein,et al.  The global distribution and burden of dengue , 2013, Nature.

[24]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[25]  Matthew Meyerson,et al.  A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1 , 2013, Science.

[26]  Michael T. McManus,et al.  Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. , 2013, Chemistry & biology.

[27]  Michael T. McManus,et al.  A Systematic Mammalian Genetic Interaction Map Reveals Pathways Underlying Ricin Susceptibility , 2013, Cell.

[28]  G. Wahl,et al.  Mechanism of action for leflunomide in rheumatoid arthritis. , 1999, Clinical immunology.

[29]  W. Knecht,et al.  Expression, purification, and characterization of histidine-tagged rat and human flavoenzyme dihydroorotate dehydrogenase. , 1998, Protein expression and purification.

[30]  J. Clardy,et al.  Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. , 2000, Structure.

[31]  U. Sauer,et al.  Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis , 2013, Science.

[32]  Peter S. Kutchukian,et al.  Rethinking molecular similarity: comparing compounds on the basis of biological activity. , 2012, ACS chemical biology.

[33]  J. Irwin,et al.  Identifying mechanism-of-action targets for drugs and probes , 2012, Proceedings of the National Academy of Sciences.

[34]  Jack Parker Davis,et al.  The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. , 1996, Biochemistry.

[35]  H. Simmonds,et al.  T-lymphocytes from AIDS Patients Are Unable to Synthesize Ribonucleotides de Novo in Response to Mitogenic Stimulation , 1995, The Journal of Biological Chemistry.

[36]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[37]  N. Perrimon,et al.  High-throughput RNAi screening in cultured cells: a user's guide , 2006, Nature Reviews Genetics.

[38]  J. Asara,et al.  Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1 , 2013, Science.

[39]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[40]  Inmar E. Givoni,et al.  Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast , 2006, Cell.

[41]  Max A. Horlbeck,et al.  Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation , 2014, Cell.

[42]  V. Simon,et al.  Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis , 2011, Proceedings of the National Academy of Sciences.

[43]  J. Weissman,et al.  Functional genomics platform for pooled screening and generation of mammalian genetic interaction maps , 2014, Nature Protocols.

[44]  J. Strum,et al.  GSK983: A novel compound with broad-spectrum antiviral activity , 2009, Antiviral Research.

[45]  E. Frolova,et al.  Interplay of Acute and Persistent Infections Caused by Venezuelan Equine Encephalitis Virus Encoding Mutated Capsid Protein , 2010, Journal of Virology.

[46]  W. Knecht,et al.  Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects? , 2001, European journal of biochemistry.

[47]  H. Simmonds,et al.  Importance of Ribonucleotide Availability to Proliferating T-lymphocytes from Healthy Humans , 1995, The Journal of Biological Chemistry.

[48]  Yuna Sun,et al.  Current progress in antiviral strategies , 2014, Trends in Pharmacological Sciences.

[49]  M. Kinch,et al.  FGI-104: a broad-spectrum small molecule inhibitor of viral infection. , 2009, American journal of translational research.

[50]  Martin Kampmann,et al.  Integrated platform for genome-wide screening and construction of high-density genetic interaction maps in mammalian cells , 2013, Proceedings of the National Academy of Sciences.